Genentech posted a 41 percent increase in its profits for the company's recently completed second quarter on Wednesday in part on the strength of its cancer drugs.

Genentech's Avastin drug, which treats lung, breast and colon cancer, saw sales for the April-June period of this year rise 33 percent to $564 million.

If you're an Avastin customer, has the drug helped with your specific cancer and have you been pleased with the results? I've never met anyone using this drug and have been curious to see what effects it does have on the cancer types it is marketed to fight against.

ImClone Systems Inc.'s drug Erbitux has failed to help pancreatic cancer patients live longer. It's also failed to grow ImClone's market -- not surprising since it's the company's only drug.

Imclone, partnering with Bristol-Myers Squibb Co., wanted to see Erbitux -- already cleared for use with colon, head, and neck cancers -- extend the lives of patients with cancer marked by a spread to the pancreas.

No one is giving up just yet, and Imclone plans additional tests on Erbitux's use in pancreatic cancer. A study using a combination of Erbitux and Avastin and chemotherapy is up next.

"There are reasons to think Erbitux works in pancreatic cancer, but the current results are not as dramatic as we hoped," said Alex Denner, lead for an executive committee that manages ImClone. "We remain committed to evaluating Erbitux in pancreatic cancer."

If approved, Erbitux will compete with Tarceva, sold by Roche Holding AG, Genentech Inc., and OSI Pharmaceuticals Inc. as a treatment for pancreatic and lung cancers.

About 37,170 new cases of pancreatic cancer are expected to occur in 2007 in the United States. And 33,370 people will die from the disease, according to the American Cancer Society. Pancreatic cancer is one of the most aggressive cancers, and there is no screening option that works at catching the disease in its early stages.

Only about 5 percent of patients with pancreatic cancer are still alive five years after being diagnosed.

Someone once told me to think of cancer as a chronic condition -- an illness like diabetes or asthma that may linger for life and may require continual treatment. And while battling cancer, perhaps for life, I should just hope that medical advances occur and new treatments become available. And maybe, just maybe, the science of medicine will decrease by leaps and bounds the number of people who die from cancer.

During my own battle with cancer -- which has been 18 months long -- two new breast cancer drugs have hit the scene with rave reviews from researchers and medical professionals. This is good news for me because my type of breast cancer makes me a candidate for both drugs. Herceptin is one of these drugs -- given to women who are HER-2/neu positive -- that's me -- and over express a protein that makes the tumor aggressive. Herceptin is received over 52 weeks -- and I go every three weeks for a 90-minute infusion of this clear liquid that causes me really no side effects at all. It can be toxic to the heart but monitoring tests have revealed that my heart is not suffering at this time. And with just three more infusions to go -- one this Wednesday -- I will likely encounter no adverse reactions to this potentially life-saving drug.

And now Tykerb is making headlines. Tykerb, suggested for use with advanced breast cancer and manufactured by British-based GlaxoSmithKline PLC, is an experimental drug that delays the growth of tumors nearly twice as long as standard chemotherapy in patients who no longer respond to Herceptin. This finding, reported this past Saturday at a meeting in Atlanta of the American Society of Clinical Oncology, confirms initial findings about the promise of this drug -- that like Herceptin, made by Genentech, precisely targets tumors without killing lots of healthy cells. The difference between the two drugs is that Herceptin blocks the protein on the cell's surface and Tykerb does it inside the cell -- blocking a second abnormal protein too. And while Herceptin is given intravenously, Tykerb is given in pill form -- which may make it cheaper and easier to use.

While now part of an international study, Tykerb may be available to women in the United States later this year. And it perhaps will be offered in conjunction with Herceptin or instead of Herceptin for women with advanced breast cancer.

I hope I do not ever need Tykerb -- and that Herceptin alone will be enough for me -- but it is comforting to know that there is something else out there. Something that if necessary, just might help me live with this potentially chronic condition called cancer.

For the first time in 25 years, cancer patients with large B-cell, CD20positive, non-Hodgkin's lymphoma, have a new drug in the treatment of their cancer. Genentech and Biogen issued a press release announcing the U.S. Food and Drug Administration, FDA, approval of Rituxan® in the treatment for large B-cell, CD20positive, non-Hodgkin's lymphoma. Large B-cell, CD20positive, non-Hodgkin's lymphoma is an aggressive cancer that can be fatal within six months to two years. Rituxan® is a therapeutic antibody that targets and selectively depletes CD20-positive B-cells without targeting stem cells or existing plasma cells, and will be administered in combination with existing chemotherapy treatments. Before this approval, Rituxan® had been used as a single agent in relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma.